CL2007002494A1 - Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion. - Google Patents

Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion.

Info

Publication number: CL2007002494A1
Authority: CL; Chile
Prior art keywords: trisustituida; pirimidine; pde5; disease; compound
Prior art date: 2006-08-29

Application number

CL200702494A

Other languages

English (en)

Inventor

Clozel Martine

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-29

Filing date

2007-08-27

Publication date

2008-04-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38954615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002494(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-08-27 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2008-04-04 Publication of CL2007002494A1 publication Critical patent/CL2007002494A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL200702494A 2006-08-29 2007-08-27 Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion. CL2007002494A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IB2006052999		2006-08-29
IB2006053857		2006-10-19

Publications (1)

Publication Number	Publication Date
CL2007002494A1 true CL2007002494A1 (es)	2008-04-04

Family

ID=38954615

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702494A CL2007002494A1 (es)	2006-08-29	2007-08-27	Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion.

Country Status (31)

Country	Link
US (8)	US8268847B2 (es)
EP (1)	EP2059246B1 (es)
JP (1)	JP5208113B2 (es)
KR (1)	KR101473022B1 (es)
CN (1)	CN101511365B (es)
AR (1)	AR062501A1 (es)
AU (1)	AU2007290099B2 (es)
BR (1)	BRPI0715698B8 (es)
CA (1)	CA2659770C (es)
CL (1)	CL2007002494A1 (es)
CY (1)	CY1114735T1 (es)
DK (1)	DK2059246T3 (es)
ES (1)	ES2438792T3 (es)
FI (1)	FIC20240045I1 (es)
FR (1)	FR24C1054I2 (es)
HR (1)	HRP20131233T1 (es)
HU (1)	HUS2400046I1 (es)
IL (1)	IL197235A (es)
LT (1)	LTPA2024537I1 (es)
MA (1)	MA30704B1 (es)
MX (1)	MX2009002057A (es)
MY (1)	MY154591A (es)
NL (1)	NL301308I2 (es)
NO (1)	NO342554B1 (es)
NZ (1)	NZ575702A (es)
PL (1)	PL2059246T3 (es)
PT (1)	PT2059246E (es)
RU (1)	RU2462249C2 (es)
SI (1)	SI2059246T1 (es)
TW (1)	TWI388556B (es)
WO (1)	WO2008026156A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007031933A2 (en)	2005-09-12	2007-03-22	Actelion Pharmaceuticals Ltd	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MX2010001837A (es)	2007-08-17	2010-03-10	Actelion Pharmaceuticals Ltd	Derivados de 4-pirimidinasulfamida.
PL2254570T3 (pl) *	2008-02-20	2014-05-30	Actelion Pharmaceuticals Ltd	Połączenie zawierające paklitaksel do leczenia raka jajnika
WO2010018549A2 (en)	2008-08-13	2010-02-18	Actelion Pharmaceuticals Ltd	Therapeutic compositions containing macitentan
TWI462739B (zh) *	2010-11-02	2014-12-01	Univ Kaohsiung Medical	Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CN102949395A (zh) *	2011-09-22	2013-03-06	荆志成	盐酸伐地那非片在制备治疗肺动脉高压药物中的应用
CN102839165B (zh) *	2012-09-26	2014-12-10	金普诺安生物科技（苏州）有限公司	基因突变型重组蛋白酶k及其工业化生产方法
CN105693624B (zh) *	2013-06-14	2018-05-18	杭州普晒医药科技有限公司	马西替坦晶体及其制备方法、其药物组合物和用途
KR20190030805A (ko)	2017-09-14	2019-03-25	경상대학교산학협력단	폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
MA54522B1 (fr) *	2018-12-21	2024-07-31	Actelion Pharmaceuticals Ltd	Macitentan pour le traitement de l'hypertension artérielle pulmonaire
TW202042818A (zh)	2019-01-25	2020-12-01	瑞士商艾克泰聯製藥有限公司	用於治療慢性血栓性肺高血壓之醫藥組成物
KR20220106974A (ko)	2019-11-29	2022-08-01	액테리온 파마슈티칼 리미티드	폐동맥 고혈압을 치료하는 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2801584A1 (de)	1978-01-14	1979-07-19	Bayer Ag	Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
US5250534A (en)	1990-06-20	1993-10-05	Pfizer Inc.	Pyrazolopyrimidinone antianginal agents
RU2086544C1 (ru)	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW394761B (en)	1993-06-28	2000-06-21	Hoffmann La Roche	Novel Sulfonylamino Pyrimidines
US5589006A (en) *	1993-11-30	1996-12-31	Canon Kabushiki Kaisha	Solar battery module and passive solar system using same
IL111959A (en)	1993-12-17	2000-07-16	Tanabe Seiyaku Co	N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
WO1996016963A1 (de)	1994-11-25	1996-06-06	F. Hoffmann-La Roche Ag	Sulfonamide und deren verwendung als heilmittel
TW313568B (es)	1994-12-20	1997-08-21	Hoffmann La Roche
US5739333A (en)	1995-05-16	1998-04-14	Tanabe Seiyaku Co., Ltd.	Sulfonamide derivative and process for preparing the same
RU2172735C2 (ru)	1995-12-20	2001-08-27	Яманоути Фармасьютикал Ко., Лтд.	Арилэтенсульфонамидные производные и фармацевтическая композиция
HRP20020585B1 (hr)	1997-11-12	2013-02-28	Bayer Schering Pharma Aktiengesellschaft	2-fenil supstituirani imidazotriazinoni kao inhibitori fosfodiesteraze
US6087368A (en)	1998-06-08	2000-07-11	Bristol-Myers Squibb Company	Quinazolinone inhibitors of cGMP phosphodiesterase
KR100353014B1 (ko)	1998-11-11	2002-09-18	동아제약 주식회사	발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
TWI284642B (en)	1999-01-18	2007-08-01	Hoffmann La Roche	Novel heterocyclic sulfonamides
EP1137642B1 (en)	1999-09-03	2007-12-05	Actelion Pharmaceuticals Ltd.	Bis-sulfonamides
TW200400821A (en)	1999-11-02	2004-01-16	Pfizer	Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
MXPA02006250A (es)	1999-12-22	2004-09-06	Actelion Pharmaceuticals Ltd	Derivados de butino diol.
WO2001081335A1 (en)	2000-04-20	2001-11-01	Actelion Pharmaceuticals Ltd	Pyrimidine-sulfonamides having endothelin-antagonist activity
WO2001081338A1 (en)	2000-04-25	2001-11-01	Actelion Pharmaceuticals Ltd	Substituted sulfonylaminopyrimidines
BRPI0116237B8 (pt)	2000-12-18	2021-05-25	Actelion Pharmaceuticals Ltd	"composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
DE10148883A1 (de) *	2001-10-04	2003-04-10	Merck Patent Gmbh	Pyrimidinderivate
US20060205733A1 (en) *	2004-08-26	2006-09-14	Encysive Pharmaceuticals	Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US7094081B1 (en)	2005-03-24	2006-08-22	Delphi Technologies, Inc.	Electrical connector assembly
WO2007031933A2 (en) *	2005-09-12	2007-03-22	Actelion Pharmaceuticals Ltd	Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MX2008013034A (es)	2006-04-13	2008-10-17	Actelion Pharmaceuticals Ltd	Antagonistas del receptor de endotelina para etapas tempranas de fibrosis pulmonar idiopatica.

2007
- 2007-08-23 AR ARP070103749A patent/AR062501A1/es not_active Application Discontinuation
- 2007-08-27 CL CL200702494A patent/CL2007002494A1/es unknown
- 2007-08-28 RU RU2009111378/15A patent/RU2462249C2/ru active
- 2007-08-28 US US12/439,290 patent/US8268847B2/en active Active
- 2007-08-28 CN CN2007800321481A patent/CN101511365B/zh active Active
- 2007-08-28 DK DK07826167.4T patent/DK2059246T3/da active
- 2007-08-28 SI SI200731367T patent/SI2059246T1/sl unknown
- 2007-08-28 BR BRPI0715698A patent/BRPI0715698B8/pt active IP Right Grant
- 2007-08-28 PL PL07826167T patent/PL2059246T3/pl unknown
- 2007-08-28 MY MYPI20090795A patent/MY154591A/en unknown
- 2007-08-28 PT PT78261674T patent/PT2059246E/pt unknown
- 2007-08-28 NZ NZ575702A patent/NZ575702A/en unknown
- 2007-08-28 ES ES07826167.4T patent/ES2438792T3/es active Active
- 2007-08-28 EP EP07826167.4A patent/EP2059246B1/en active Active
- 2007-08-28 HR HRP20131233TT patent/HRP20131233T1/hr unknown
- 2007-08-28 JP JP2009526239A patent/JP5208113B2/ja active Active
- 2007-08-28 WO PCT/IB2007/053448 patent/WO2008026156A2/en not_active Ceased
- 2007-08-28 TW TW096131928A patent/TWI388556B/zh active
- 2007-08-28 KR KR1020097005029A patent/KR101473022B1/ko active Active
- 2007-08-28 CA CA2659770A patent/CA2659770C/en active Active
- 2007-08-28 AU AU2007290099A patent/AU2007290099B2/en active Active
- 2007-08-28 MX MX2009002057A patent/MX2009002057A/es active IP Right Grant
2009
- 2009-02-25 IL IL197235A patent/IL197235A/en active IP Right Grant
- 2009-03-06 MA MA31695A patent/MA30704B1/fr unknown
- 2009-03-26 NO NO20091254A patent/NO342554B1/no unknown
2012
- 2012-09-05 US US13/604,148 patent/US20130210830A9/en not_active Abandoned
2013
- 2013-12-27 CY CY20131101163T patent/CY1114735T1/el unknown
2014
- 2014-01-23 US US14/162,280 patent/US20140148460A1/en not_active Abandoned
2018
- 2018-01-26 US US15/881,060 patent/US20180147205A1/en not_active Abandoned
- 2018-11-16 US US16/193,859 patent/US20190083494A1/en not_active Abandoned
2019
- 2019-10-11 US US16/599,582 patent/US20200038401A1/en not_active Abandoned
2020
- 2020-07-30 US US16/942,895 patent/US20200352944A1/en not_active Abandoned
2021
- 2021-02-25 US US17/185,238 patent/US20210177849A1/en not_active Abandoned
2024
- 2024-12-16 FR FR24C1054C patent/FR24C1054I2/fr active Active
- 2024-12-16 FI FIC20240045C patent/FIC20240045I1/fi unknown
- 2024-12-17 HU HUS2400046C patent/HUS2400046I1/hu unknown
- 2024-12-17 LT LTPA2024537C patent/LTPA2024537I1/lt unknown
- 2024-12-18 NL NL301308C patent/NL301308I2/nl unknown

Also Published As

Publication number	Publication date
AR062501A1 (es)	2008-11-12
US20190083494A1 (en)	2019-03-21
MA30704B1 (fr)	2009-09-01
PT2059246E (pt)	2013-12-16
KR20090057009A (ko)	2009-06-03
NO342554B1 (no)	2018-06-11
PL2059246T3 (pl)	2014-03-31
RU2462249C2 (ru)	2012-09-27
CA2659770A1 (en)	2008-03-06
RU2009111378A (ru)	2010-10-10
MY154591A (en)	2015-06-30
US20200038401A1 (en)	2020-02-06
HK1133597A1 (en)	2010-04-01
US20090318459A1 (en)	2009-12-24
AU2007290099A1 (en)	2008-03-06
DK2059246T3 (da)	2013-12-02
BRPI0715698B8 (pt)	2021-05-25
AU2007290099B2 (en)	2013-01-31
NL301308I2 (nl)	2024-12-30
ES2438792T3 (es)	2014-01-20
US20140148460A1 (en)	2014-05-29
CN101511365A (zh)	2009-08-19
CY1114735T1 (el)	2017-01-25
MX2009002057A (es)	2009-03-06
TWI388556B (zh)	2013-03-11
FIC20240045I1 (fi)	2024-12-16
US20130005734A1 (en)	2013-01-03
NO20091254L (no)	2009-03-26
BRPI0715698A2 (pt)	2013-08-06
KR101473022B1 (ko)	2014-12-15
HUS2400046I1 (hu)	2025-01-28
NZ575702A (en)	2011-11-25
WO2008026156A3 (en)	2008-10-16
CN101511365B (zh)	2011-08-17
US20130210830A9 (en)	2013-08-15
IL197235A (en)	2014-04-30
FR24C1054I2 (fr)	2025-10-17
TW200823198A (en)	2008-06-01
EP2059246B1 (en)	2013-10-16
EP2059246A2 (en)	2009-05-20
JP2010502588A (ja)	2010-01-28
US8268847B2 (en)	2012-09-18
WO2008026156A2 (en)	2008-03-06
BRPI0715698B1 (pt)	2020-01-21
LTPA2024537I1 (es)	2025-01-10
SI2059246T1 (sl)	2014-01-31
CA2659770C (en)	2014-11-18
US20200352944A1 (en)	2020-11-12
JP5208113B2 (ja)	2013-06-12
IL197235A0 (en)	2009-12-24
US20180147205A1 (en)	2018-05-31
HRP20131233T1 (hr)	2014-01-31
US20210177849A1 (en)	2021-06-17
FR24C1054I1 (fr)	2025-02-21

Similar Documents

Publication	Publication Date	Title
CL2007002494A1 (es)	2008-04-04	Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion.
CL2007001992A1 (es)	2008-07-18	Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
CL2007002967A1 (es)	2008-04-18	Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un
CL2007003523A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
CL2007002916A1 (es)	2008-04-18	Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
CL2007003520A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007003138A1 (es)	2008-06-27	Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2013001136A1 (es)	2014-03-07	Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
CL2007002261A1 (es)	2008-05-02	Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
CL2007002207A1 (es)	2008-02-01	Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CL2007002866A1 (es)	2008-07-04	Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
CL2007003552A1 (es)	2008-07-18	Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular.
CL2007003444A1 (es)	2008-06-27	Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
CL2007002641A1 (es)	2008-06-20	Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2007002234A1 (es)	2008-06-13	Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2007003718A1 (es)	2008-07-11	Compuestos macrociclos, inhibidores selectivos del factor viia de coagulacion de serinaproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de un trastorno tromboembolico.
CL2007003202A1 (es)	2008-03-07	Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2008001076A1 (es)	2008-10-24	Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007001993A1 (es)	2008-06-20	Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
CL2007003244A1 (es)	2008-04-04	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008000510A1 (es)	2008-08-22	Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero.
CL2007001724A1 (es)	2008-05-09	Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
EP2037917A4 (en)	2010-08-04	Pharmaceutical composition comprising amlodipine and losartan
CL2007003038A1 (es)	2008-06-06	Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.